ACADIA PHARMACEUTICALS INC (ACAD)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 264,566 | 244,317 | 250,401 | |
| Selling, general and administrative | 133,507 | 126,370 | 133,294 | |
| Research and development | 77,951 | 78,265 | 66,606 | |
| Cost of product sales | 20,734 | 20,392 | 18,857 | |
| Total operating expenses | 232,192 | 225,027 | 218,757 | |
| Income from operations | 32,374 | 19,290 | 31,644 | |
| Interest income, net | 7,243 | 7,901 | 6,586 | |
| Other income | 594 | 588 | 576 | |
| Income before income taxes | 40,211 | 27,779 | 38,806 | |
| Income tax expense | 13,545 | 8,792 | 6,041 | |
| Net loss | 26,666 | 18,987 | 32,765 | |
| Earnings (net loss) per share, diluted | 0.16 | 0.11 | 0.2 | |
| Earnings per share, basic, total | 0.16 | 0.11 | 0.2 | |
| Weighted average common shares outstanding, basic | 167,827,000 | 166,808,000 | 165,974,000 | |
| Weighted average common shares outstanding, diluted | 168,681,000 | 167,668,000 | 166,178,000 | |